<DOC>
	<DOCNO>NCT02206867</DOCNO>
	<brief_summary>To compare PK , safety tolerability LBAL develop LG Life Sciences Ltd. With Humira® .</brief_summary>
	<brief_title>Pharmacokinetics Safety Study LBAL Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Adalimumab</mesh_term>
	<mesh_term>Anti-Inflammatory Agents</mesh_term>
	<criteria>1 . 2045 year old healthy male 2 . Body mass index 19.0 ~ 28.0 kg/m2 1 . Diagnosis current latent tuberculosis ( TB ) ; history severe active chronic local infection include TB 2 . Severe infection ( e.g . sepsis ) require admission antibiotic treatment within four week prior administration 3 . Clinically relevant previous concomitant disease include hepatic , renal , neurological , respiratory , gastrointestinal , endocrine , hematologic , oncologic , cardiovascular , urinary , musculoskeletal psychiatric , autoimmune disease/disorders 4 . Chronic relevant acute infection . A negative result human immunodeficiency virus ( HIV ) , Hepatitis B ( Hep B ) , hepatitis C ( Hep C ) require participation ( i.e . HIV Ab , HBsAg , HBcAb , HCV Ab ) 5 . Fever great 38.3℃ within week prior administration study drug 6 . Previous current drug abuse</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>